Longeveron

42 articles with Longeveron

• Longeveron to Present at Noble Capital Markets Virtual Investor Forum during the 16th Annual World Stem Cell Summit

  6/15/2021

  Longeveron Inc., a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced that Geoff Green, Chief Executive Officer of Longeveron, will present virtually at the Investor Forum at the World Stem Cell Summit on Thursday, June 17th at 9:45 AM EDT.

• Longeveron’s Chairman and Chief Science Officer Invited by National Academy of Medicine to Speak at Longevity Symposium Joshua M. Hare, MD to participate in symposium “Transformative Advances in Biological Sciences for Healthy Longevity”

  6/10/2021

  Longeveron Inc. announced that its Co-founder and Chairman, Joshua M. Hare, MD, will be a panelist at the National Academy of Medicine’s International Workshop on Science & Technology for Healthy Longevity on June 15 & 17, 2021.

• Longeveron Announces the Appointment of Ursula Ungaro to its Board of Directors

  5/25/2021

  Longeveron Inc., a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced that Ursula Ungaro will be joining its Board of Directors as of June 1, 2021.

• Longeveron Announces the Hiring of Dan Gincel, Ph.D., as Senior Vice President, Strategic Collaborations & Scientific Affairs

  5/18/2021

  Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the hiring of Dan Gincel, Ph.D. as Senior Vice President, Strategic Collaborations & Scientific Affairs.

• Longeveron Inc. Provides Corporate Update and Reports First Quarter 2021 Financial Results

  5/14/2021

  Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today provided a business update regarding a number of ongoing clinical trials, and also reported its financial results for the first quarter ended March 31, 2021.

• Longeveron to Release First Quarter 2021 Financial Results and Hold Conference Call on May 14, 2021

  5/11/2021

  Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that the Company will release its first quarter 2021 financial results on Friday, May 14, 2021 before the open of US markets.

• Longeveron Invited to Present at the Benzinga Global Small Cap Conference

  5/5/2021

  Longeveron recently announced positive results from a Phase 1 study of Lomecel-B in Alzheimer's disease, and the completion of two Phase 2 clinical trials evaluating the safety and efficacy of Lomecel-B infusion in Aging Frailty subjects. Top-line results from the Aging Frailty studies are anticipated in Q3 2021

• Longeveron Selected to Present at the 2021 World Stem Cell SummitDr. Joshua Hare, Longeveron’s Chief Science Officer, to present during this year’s Longevity Session

  4/27/2021

  Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announces it has been selected to present at the 2021 World Stem Cell Summit taking place virtually on June 14-18,

• Longeveron Announces Successful Completion of Phase I/II Clinical Study of Lomecel-B Infusion in Aging Frailty Subjects to Improve Immune Response Following Influenza Vaccination

  4/15/2021

  Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today the completion of the Company’s Phase I/II clinical study of the use of Lomecel-B to improve immune response to influenza (“flu”) vaccine in subjects with Aging Frailty.

• Longeveron Announces Positive Results of Phase I Clinical Study of Lomecel-B Cell Therapy for Alzheimer’s Disease

  4/13/2021

  Study meets primary safety endpoint; positive secondary efficacy assessments support potential benefit from Lomecel-B Decline in cognitive function slower in patients who received low-dose Lomecel-B as compared with placebo Quality of life metrics improved with Lomecel-B compared to placebo Complete results being prepared for publication. On track to initiate Phase 2 study in the second half of 2021.

• Longeveron Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results

  3/30/2021

  Longeveron Inc., a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, reported its financial results for the quarter and full year ended December 31, 2020 and provided a business update.

• Longeveron Schedules 2020 Fiscal Year End Business Update Conference Call

  3/26/2021

  Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced it will host a conference call at 8:30 a.m. Eastern Time on Tuesday, March 30, 2021 to discuss its fiscal 2020 financial results and provide a business update.

• Longeveron Inc. to Present at the Q1 Virtual Investor Summit on March 24

  3/19/2021

  Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that Geoff Green, CEO of Longeveron, will be presenting at the Q1 Virtual Investor Summit.

• Longeveron Inc. Announces Partial Exercise of Over-Allotment Option in Initial Public Offering

  3/15/2021

  Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that the underwriters of its previously completed initial public offering of Class A common stock have partially exercised their over-allotment option to purchase an additional 250,000 shares.

• Longeveron’s Lomecel-B™ Approved by FDA for Compassionate Use for the Treatment of Child with Hypoplastic Left Heart Syndrome (HLHS)

  3/11/2021

  Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced today that the U.S. Food & Drug Administration (FDA) has granted expanded access approval for the administration of Longeveron’s investigational cell therapy Lomecel-B to a child with Hypoplastic Left Heart Syndrome (HLHS).

• Longeveron and University of Miami Expand Exclusive License Agreement, and Enter into CRADA To Facilitate Future Collaborations

  3/10/2021

  Agreement Provides Additional Intellectual Property and Clinical Data for Longeveron While Strengthening Research and Development Relationship

• Longeveron Expands Enrollment Criteria for its Phase 1 RECOVER Trial Evaluating Lomecel-B Infusion to Treat Acute Respiratory Distress Syndrome due to COVID-19 or Influenza Infection

  3/5/2021

  Longeveron Inc., a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced that enrollment criteria for its Phase 1 Acute Respiratory Distress Syndrome RECOVER trial has been expanded to include mild ARDS, in addition to moderate and severe ARDS.

• Longeveron Announces Successful Completion of Phase 2b Clinical Study of Lomecel-B Infusion to Treat Aging Frailty

  3/3/2021

  Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced today the completion of the Company’s Phase 2b clinical study of Lomecel-B infusion for Aging Frailty subject

• Longeveron Announces Successful Completion of Phase 1 Clinical Study of Lomecel-B Intramyocardial Injection in Hypoplastic Left Heart Syndrome Patients

  2/24/2021

  Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, is pleased to announce completion of the Company’s Phase 1 clinical study of Lomecel-B in Hypoplastic Left Heart Syndrome (HLHS).

• CEO of Longeveron Inc. to Present at the Intercontinental Summit on Aging & Gerontology

  2/19/2021

  Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that Geoff Green, Chief Executive Officer of Longeveron, has been invited to give a presentation titled “A Regenerative Medicine Approach to Aging Frailty” at the Intercontinental Summit on Aging & Gerontology being held virtually on March 8, 2021